Buzzard Pharmaceuticals is a biopharmaceutical development company. We are developing Isunakinra, an IL-1 inhibitor for the treatment of cancer. Isunakinra (EBI-005) is a recombinant protein binding to the IL1R1 with high potency. IL-1 mediates the recruitment of immunesuppressive myeloid cells (PMN-MDSCs, neutrophils and T2 macrophages) to the tumor - that inhibit CD8 T cells from entering the tumor and killing tumor cells. Moreover, IL-1 stimulates angiogensis and tumor spread.
Company Details
- Employees
- 5
- Address
- Fogdevreten 2a, Solna,17165,sweden
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://www.buzzardpharma.com
- Keywords
- Cantargia AB.
- HQ
- Solna
Buzzard Pharmaceuticals Questions
Buzzard Pharmaceuticals's website is http://www.buzzardpharma.com
Buzzard Pharmaceuticals's LinkedIn profile is https://se.linkedin.com/company/buzzard-pharmaceuticals
Buzzard Pharmaceuticals has
5 employees.
View email and phone details for 5
employees at Buzzard Pharmaceuticals.
Buzzard Pharmaceuticals's industry is
Pharmaceutical Manufacturing
Buzzard Pharmaceuticals's top competitors are
Sixera Pharma,
Key2brain Ab,
Affibody Ab,
Abera Bioscience Ab,
Ascelia Pharma Ab,
Immuneed,
Atrogi,
Diamyd Medical,
Cantargia Ab,
Guard Therapeutics.
Buzzard Pharmaceuticals's categories are Pharmaceutical Manufacturing
